• Enzymlogic receives the Seal of Excellence from European Commission

    Enzymlogic receives the Seal of Excellence from European Commission

    Enzymlogic receives the EIC Accelerator Seal of Excellence, a quality label that identifies companies with high quality project proposals under the European Union’s research and innovation program “Horizon 2020”. The EIC Accelerator is a funding instrument, designed for deep-tech companies and start-ups, which invests in radically new ideas to expedite rolling out of marketable innovation solutions. Notoriously…

  • Enzymlogic announces US and EU Patents for Binding Kinetic Profiling in Drug Discovery

    Enzymlogic announces US and EU Patents for Binding Kinetic Profiling in Drug Discovery

    Enzymlogic, a leading analytical CRO specializing in binding kinetic profiling for drug discovery, today announced that the European Patent Office has issued EU patent EP3350596B1 covering a novel method for determining kinetic profiles in drug discovery. This proprietary technology is applicable to the early stages of drug discovery, enabling key insight into important factors that…

  • Enzymlogic receives the SME Instrument Phase I grant from the Horizon 2020 program

    Enzymlogic receives the SME Instrument Phase I grant from the Horizon 2020 program

    The KINETICfinder® platfom developed by Enzymlogic has received recognition from the European Commission, and funding from the SME Instrument project Phase 1 within the Horizon 2020 Research and Innovation Framework Programme. The KINETICfinder® platfom developed by Enzymlogic has received recognition from the European Commission, and funding from the SME Instrument project Phase 1 within the…

  • Enzymlogic’s KINETICfinder® to be featured in podium presentation at SLAS Europe 2019 International Conference & Exhibition.

    Enzymlogic’s KINETICfinder® to be featured in podium presentation at SLAS Europe 2019 International Conference & Exhibition.

    Enzymlogic has been selected by the Society for Laboratory Automation and Screening (SLAS) Scientific Programme Committee to give a Podium Presentation on June 28 in Barcelona, Spain. Enzymlogic has been selected by the SLAS (Society for Laboratory Automation and Screening) Europe 2019 Scientific Programme Committee to give a Podium Presentation highlighting the company’s KINETICfinder® technology…

  • Enzymlogic presents its Binding Kinetics Platform at 18th Drug Discovery Summit

    Enzymlogic presents its Binding Kinetics Platform at 18th Drug Discovery Summit

    A Binding Kinetics Platform that boosts the understanding of drug efficacy in vivo. Enzymlogic announce the presentation of results achieved with its Binding Kinetic Platform in the evaluation of the kinetic profile of kinase-marketed drugs. The poster entitled “Profiling the kinetic selectivity of kinase As the kickoff to the 18th Drug Discovery Summit in Berlin, Germany on June…

  • Profiling the kinetic selectivity of kinase marketed drugs

    Profiling the kinetic selectivity of kinase marketed drugs

    Enzymlogic announce the presentation of results achieved with its Binding Kinetic Platform in the evaluation of the kinetic profile of kinase-marketed drugs. Enzymlogic announce the presentation of results achieved with its Binding Kinetic Platform in the evaluation of the kinetic profile of kinase-marketed drugs. The poster entitled “Profiling the kinetic selectivity of kinase marketed drugs” will be presented at…

  • Esteve and Enzymlogic join together to drive GPCR drug discovery

    Esteve and Enzymlogic join together to drive GPCR drug discovery

    Enzymlogic has entered into a research collaboration agreement with Esteve whereby Enzymlogic will direct its novel Binding Kinetics Platform to characterize selected compounds against mu-Opioid receptor. The collaboration combines Enzymlogic’s unique Binding Kinetics Platform and vast experience kinetically screening kinase inhibitors with the GPCR expertise from Esteve. GPCRs are the largest class of membrane proteins in…

  • Enzymlogic, winner at Entrepreneur XXI Awards

    Enzymlogic, winner at Entrepreneur XXI Awards

    Enzymlogic was announced the winner of the Most Innovative Startup Award and one of the three finalist in the Life Science category at the prestigious Entrepreneur XXI Awards ceremony. The ceremony marks the culmination of a year-long decision-making process which began with over 545 applications and ended with just 15 finalists attending the event in the…

  • Expanding our kinetic services globally

    Expanding our kinetic services globally

    Enzymlogic has been granted with the ICEX Next programme for internationalization. ICEX Next combines consulting and economic funding to promote the internationalization of the Spanish companies. This integral practical programme supports the companies along the different phases of their international projects, both in the initiation and consolidation in foreign markets. About Enzymlogic Enzymlogic offers in vitro…

  • Enzymlogic selected as a Top 12 Startup for South Summit 2016

    Enzymlogic selected as a Top 12 Startup for South Summit 2016

    Binding kinetics platform participated as a finalist in the Health category of South Summit Startup Competition. Enzymlogic’s Binding Kinetics platform, a drug discovery platform for biotech and pharma companies, was chosen among 3000 applicants as one of 100 finalists to participate in South Summit’s Startup Competition in Madrid. The company presented its innovative platform in the health…

Events

Tweets